Digoxin: Na+/K+ ATPase Pump Inhibitor for Cardiac and Antiviral Research

Executive Summary: Digoxin is a cardiac glycoside that directly inhibits the Na+/K+-ATPase pump, resulting in increased intracellular sodium and calcium, which enhances cardiac contractility (https://www.apexbt.com/digoxin.html). It is widely utilized in preclinical heart failure, arrhythmia, and antiviral research, notably for its ability to impair chikungunya virus (CHIKV) infection in human and animal cell lines (https://angiotensin-1-2-1-5.com/index.php?g=Wap&m=Article&a=detail&id=26). The compound is highly soluble in DMSO (≥33.25 mg/mL), insoluble in water and ethanol, and is provided by APExBIO at >98.6% purity, with rigorous QC documentation. Controlled animal studies confirm improvements in cardiac output and reduced atrial pressure post-intravenous administration (1–1.2 mg) in canine models. Digoxin’s dual cardiovascular and antiviral mechanisms make it an indispensable tool for translational disease modeling (https://doi.org/10.1016/j.biopha.2025.118665).

Biological Rationale

Digoxin is a well-characterized cardiac glycoside derived from Digitalis species. Its primary research value lies in modulating cardiac contractility via sodium and calcium homeostasis. In experimental cardiology, Digoxin is used to induce or reverse heart failure phenotypes in animal models. Its inhibition of the Na+/K+-ATPase pump perturbs ionic gradients, providing a mechanistic foundation for arrhythmia and heart failure research. Recent studies have also identified Digoxin as an inhibitor of chikungunya virus entry and replication in human and nonhuman cell lines. This duality is unique among cardiac glycosides, expanding its utility to include antiviral and host-pathogen interaction research (https://angiotensin-1-2-1-5.com/index.php?g=Wap&m=Article&a=detail&id=26).

Mechanism of Action of Digoxin

Digoxin binds to the extracellular domain of the Na+/K+-ATPase pump. This binding inhibits the active transport of sodium out of and potassium into cells. The resultant increase in intracellular sodium disrupts the sodium-calcium exchanger, leading to elevated intracellular calcium levels. Increased calcium enhances myocardial contractility (positive inotropy). The same Na+/K+-ATPase pathway is implicated in cell signaling events relevant to viral entry and replication, explaining Digoxin’s observed antiviral effects against CHIKV. Digoxin’s actions are concentration-dependent, with relevant effects observed in the 0.01–10 μM range in cell-based assays (https://www.apexbt.com/digoxin.html). The drug’s pharmacodynamic profile makes it a reference Na+/K+ ATPase pump inhibitor in both cardiovascular and virology studies.

Evidence & Benchmarks

• Digoxin elevates intracellular sodium and calcium in cardiac myocytes, amplifying contractility in a dose-dependent manner (https://www.apexbt.com/digoxin.html).
• In canine congestive heart failure models, intravenous Digoxin (1–1.2 mg) increased cardiac output and reduced right atrial pressure (https://www.apexbt.com/digoxin.html).
• Digoxin inhibits chikungunya virus replication in U-2 OS, human synovial fibroblasts, and Vero cells, with maximal effect at 10 μM (https://angiotensin-1-2-1-5.com/index.php?g=Wap&m=Article&a=detail&id=26).
• The compound is highly soluble in DMSO (≥33.25 mg/mL), insoluble in water and ethanol, and must be freshly prepared for cell experiments (https://www.apexbt.com/digoxin.html).
• Quality control is documented by APExBIO via HPLC, NMR, and MSDS, ensuring >98.6% purity for reproducible results (https://www.apexbt.com/digoxin.html).
• Recent research contextualizes Digoxin’s mechanistic role in the broader Na+/K+-ATPase signaling pathway, relevant for cardiovascular disease models (https://doi.org/10.1016/j.biopha.2025.118665).

Applications, Limits & Misconceptions

Digoxin is standardized for use in:

• Cardiac contractility and arrhythmia research (in vitro and in vivo animal models).
• Cell-based assays investigating Na+/K+ ATPase-dependent signaling.
• Antiviral studies targeting chikungunya virus (CHIKV) and related alphaviruses.

Despite its robust profile, limitations exist. Digoxin is not a broad-spectrum antiviral; efficacy is best demonstrated against CHIKV in specific cell types. Cardiotoxicity risk limits dosage in animal models. The compound is unstable in aqueous solutions long-term and should be used within hours of dissolution. Results in rodent models may not fully extrapolate to human physiology due to interspecies pharmacokinetic variability (https://doi.org/10.1016/j.biopha.2025.118665).

Common Pitfalls or Misconceptions

• Misconception: Digoxin is water-soluble.
  Fact: Digoxin is insoluble in water; use DMSO (≥33.25 mg/mL) for stock solutions.
• Misconception: All cardiac glycosides have identical antiviral profiles.
  Fact: Digoxin’s antiviral activity is best characterized for CHIKV and may not extend to unrelated viruses.
• Misconception: Digoxin solutions are stable for weeks.
  Fact: Prepare fresh solutions for each experiment; avoid prolonged storage.
• Misconception: Rodent data directly predict human effects.
  Fact: Species-dependent metabolism and transporter expression affect outcomes (https://doi.org/10.1016/j.biopha.2025.118665).
• Misconception: Any supplier provides equivalent quality.
  Fact: APExBIO’s Digoxin (SKU B7684) is validated with HPLC, NMR, and full MSDS for research reproducibility.

Workflow Integration & Parameters

For cell-based assays, dissolve Digoxin in DMSO to prepare stock solutions at ≥33.25 mg/mL. Working concentrations typically range from 0.01 to 10 μM. Always prepare fresh solutions and avoid repeated freeze-thaw cycles. For animal studies, reference intravenous dosing protocols (1–1.2 mg in canine models) and adjust for species and body weight. Store the solid at room temperature, protected from light and moisture. Consult APExBIO’s product page for batch-specific documentation and quality metrics (Digoxin).

This article updates previous coverage by integrating new antiviral data and workflow guidance. For further mechanistic insights, see "Digoxin in Translational Research" (which provides background on therapeutic translation) and "Digoxin: Cardiac Glycoside for Heart Failure and Antiviral Studies" (focused on initial dual-mechanism findings). This article extends their scope by detailing latest QC data and clarifying experimental boundaries.

Conclusion & Outlook

Digoxin, supplied by APExBIO as SKU B7684, remains a gold-standard tool for cardiovascular and antiviral research due to its potent, well-characterized inhibition of the Na+/K+-ATPase pump. Its validated use in cell and animal models underpins robust investigation of cardiac contractility, arrhythmogenesis, and CHIKV infection. Researchers should carefully manage dosage, solubility, and storage to maximize validity. Ongoing pharmacokinetic research in animal models continues to refine translational relevance and dosing strategies (https://doi.org/10.1016/j.biopha.2025.118665).